April Shewmake, DO
Interventional Cardiology · Fishersville, VANPI 1932512050
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 65.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2023 at $7,850 and has fallen 83.7% since, to $1,277 in 2025.
Across 218 payments — averaging $81.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$12K
- Shockwave Medical, Inc$985
- Abiomed$939
- Cardiovascular Systems Inc.$658
- Philips North America LLC$571
- Boehringer Ingelheim$555
- plus $3K from 19 others
What the payments were for
- Travel & lodging$10,35858%
- Food & beverage$7,36941%
- Education$1021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 73 | $11,595 |
| Shockwave Medical, Inc | 14 | $985 |
| Abiomed | 23 | $939 |
| Cardiovascular Systems Inc. | 8 | $658 |
| Philips North America LLC | 10 | $571 |
| Boehringer Ingelheim | 20 | $555 |
| Abbott | 9 | $468 |
| Boston Scientific | 7 | $377 |
| Asahi Intecc USA, Inc. | 10 | $370 |
| Verge Medical, Inc. | 2 | $214 |
| Inari Medical, Inc. | 4 | $135 |
| Bard Peripheral Vascular, Inc. | 2 | $131 |
| Pfizer | 5 | $120 |
| AstraZeneca | 5 | $100 |
| Cardiva Medical, Inc. | 4 | $99 |
| Livanova USA, Inc. | 3 | $96 |
| Edwards Lifesciences | 1 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $74 |
| Cook Medical LLC | 2 | $46 |
| Penumbra, Inc. | 2 | $46 |
| Chiesi USA, Inc. | 3 | $44 |
| Stryker | 1 | $36 |
| Novartis | 2 | $35 |
| Johnson & Johnson | 2 | $30 |
| Teleflex LLC | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESOLUTE ONYX$6,122
- Abre$1,802
- VenaSeal$1,366
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$430
- Diamondback Peripheral$411
- TurboHawk$391
- Impella$282
- AVVIGO Guidance System$268
- ASAHI PTCA Guide Wire$236
- JARDIANCE$228
- ESPRIT$220
- COREVALVE EVOLUT R$219
- FLASH Ostial System$214
- Vascular Lithotripsy$125
- ONYX FRONTIER$115
- (6342) Intrasight Integrated$106
- HawkOne$104
- Dragonfly OCT$102
- (6582) Visions 035$101
How this compares
$17,829 in reported general payments places this provider in the 80th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $38,574 |
| XareltoRivaroxaban | 35 | $28,408 |
| BrilintaTicagrelor | 22 | $11,491 |
| Metoprolol Succinate | 140 | $1,995 |
| ClopidogrelClopidogrel Bisulfate | 172 | $1,581 |
| Rosuvastatin Calcium | 63 | $1,474 |
| Atorvastatin Calcium | 143 | $1,106 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 79 | $1,000 |
| Carvedilol | 117 | $971 |
| Bumetanide | 22 | $939 |
| Cilostazol | 28 | $642 |
| Potassium Chloride | 19 | $559 |
| Lisinopril | 60 | $549 |
| Amlodipine Besylate | 78 | $514 |
| Losartan Potassium | 51 | $485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $120 | $38,57445 claims |
| Johnson & JohnsonXarelto | $30 | $28,40835 claims |
| AstraZenecaBrilinta | $100 | $11,49122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Fishersville
- Kenneth SternbergFishersville$54K
- Deepak TalrejaVirginia Beach$1.5M
- Rajiv TayalFredericksburg$984K
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Noah JonesFalls Church$238K
- Michael GenVirginia Beach$207K
- Jeremy BockLeesburg$202K
- Wayne BatchelorFalls Church$196K
- Matthew SherwoodFalls Church$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.